Chemical inhibitors of Btnl1 can exert their functional inhibition through various mechanisms primarily related to the regulation of acetylation within the cellular environment. Trichostatin A, Vorinostat, Entinostat, Romidepsin, Panobinostat, Belinostat, Chidamide, Givinostat, Valproic Acid, Sodium Butyrate, SAHA, and Mocetinostat are all histone deacetylase (HDAC) inhibitors that can alter the acetylation status of histones and other proteins within the cell. This alteration in acetylation can disrupt the interaction between Btnl1 and chromatin, thereby inhibiting Btnl1's function. For instance, Trichostatin A can lead to hyperacetylation of histones, which may disrupt Btnl1's chromatin-related interactions or functions. Similarly, Vorinostat can interfere with Btnl1's function by altering the acetylation status of proteins within Btnl1's signaling pathways.
Moreover, Entinostat's selective inhibition of Class I HDACs can affect Btnl1's involvement in acetylation-dependent signaling pathways, while Romidepsin can change acetylation patterns, affecting Btnl1's role in immune response. Panobinostat's broad HDAC inhibitory activity can dysregulate acetylation-related mechanisms, potentially inhibiting Btnl1's activity. Belinostat may interfere with Btnl1's function in T-cell regulation by altering acetylation processes. Chidamide's impact on acetylation balance could disrupt Btnl1-dependent immune signaling, while Givinostat's inhibition of HDACs may affect chromatin accessibility and Btnl1's subsequent interaction with immune signaling molecules. Valproic Acid's role as an HDAC inhibitor can alter protein acetylation involved in Btnl1 pathways. Sodium Butyrate can cause hyperacetylation of histones, potentially interfering with Btnl1's immune response regulation. SAHA, by altering histone acetylation, can inhibit Btnl1's interactions with other immune regulatory proteins, and Mocetinostat's inhibition of Class I/IV HDACs can affect the acetylation pattern, thus inhibiting Btnl1's immune regulatory functions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Inhibits HDACs leading to hyperacetylation of histones, thereby potentially disrupting Btnl1's interaction with chromatin. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
HDAC inhibitor that could alter the acetylation status of proteins and potentially interfere with Btnl1's function. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $88.00 $208.00 | 24 | |
Selectively inhibits Class I HDACs, potentially affecting Btnl1's involvement with acetylation-dependent signaling pathways. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $214.00 $622.00 | 1 | |
HDAC inhibitor that could change the acetylation patterns, indirectly affecting Btnl1's role in immune response. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $196.00 | 9 | |
Broad HDAC inhibitor that could dysregulate acetylation-related mechanisms, potentially inhibiting Btnl1's activity. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $153.00 $561.00 | ||
HDAC inhibitor that may interfere with acetylation processes and indirectly inhibit Btnl1's function in T-cell regulation. | ||||||
Chidamide | 743420-02-2 | sc-364462 sc-364462A sc-364462B | 1 mg 5 mg 25 mg | $61.00 $245.00 $1173.00 | ||
HDAC inhibitor that could perturb the acetylation balance, potentially disrupting Btnl1-dependent immune signaling. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $85.00 | 9 | |
HDAC inhibitor that could indirectly inhibit Btnl1 by altering the acetylation status of proteins involved in Btnl1 pathways. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $30.00 $46.00 $82.00 $218.00 | 19 | |
HDAC inhibitor that could cause hyperacetylation of histones, possibly interfering with Btnl1's role in immune response regulation. | ||||||
Mocetinostat | 726169-73-9 | sc-364539 sc-364539B sc-364539A | 5 mg 10 mg 50 mg | $210.00 $242.00 $1434.00 | 2 | |
Inhibits Class I/IV HDACs, which could affect the acetylation pattern and indirectly inhibit Btnl1's immune regulatory functions. | ||||||